PINE BROOK, N.J. -- (BUSINESS WIRE) -- Alvogen Inc. (“Alvogen”), the multinational pharmaceuticals company today announced that Darren Alkins has joined the company as President of Alvogen Americas and will become a member of the Group’s Executive Board.
Darren brings 25 years of commercial experience from the industry in brand and generic sales and marketing, as well as third party business development. He successfully led the Business Development and Alliance Management team for Teva Pharmaceuticals, driving key organizational initiatives developing new and existing business for the company in the US. He also served as the Senior Vice President of Corporate Development at Stiefel Laboratories and President of Glades Pharmaceuticals. Darren started the first 16 years of his career with Bristol-Myers Squibb, promoted through various sales, marketing, operations and business development functions.
Darren will be leading Alvogen’s sales, marketing and business development efforts in North- and South America. He will also be responsible for Alvogen’s third party business units in the U.S., including Norwich Pharma Services, a contract manufacturing and clinical research organization based in Norwich, New York.
“I am delighted to welcome Darren to the Executive Board, a role for which he is well prepared through his extensive industry experience. With more than 25 years of commercial experience in both branded and generic pharmaceuticals, Darren’s successful history driving key organizational initiatives, expertise and leadership will help lead Alvogen into our next phase of growth”, said Robert Wessman, Chairman and CEO of Alvogen.
“In just a few years, Alvogen has built a robust pipeline and strong commercial platforms across the globe,” commented Alkins. “I look forward to building on that momentum in the Americas as we find and develop new business opportunities and expand the reach of current products.”
Alvogen is a multinational, privately-owned pharmaceuticals company, focused on developing, manufacturing and distributing generic, brand, over-the-counter brands (OTC) and biosimilar products. With more than 200 pharmaceutical projects in development and registration, the group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has commercial operations in over 30 countries with 1,900 employees. Alvogen welcomes inquiries regarding partnering opportunities. Please contact Alexander Mironov, Vice President, Business Development, at +1.973.487.3951 for more information.